Stay updated with breaking news from Tim Dyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small...
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care.
Monday, Addex Therapeutics (NASDAQ:ADXN) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The company is collaborating with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals Inc. The Phase 2 study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was